Literature DB >> 2177499

Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans.

L M Golub1, S Ciancio, N S Ramamamurthy, M Leung, T F McNamara.   

Abstract

Tetracyclines are now recognized to have non-antimicrobial properties with therapeutic potential--for example, these agents can inhibit pathologic collagenolysis by blocking mammalian collagenases and other matrix-degrading metalloproteinases. In the current study, adult human subjects with moderate chronic periodontitis were administered specially formulated capsules of doxycycline, containing lower-than-usual amounts of this semi-synthetic tetracycline, on a daily basis for 2 weeks prior to a full-thickness flap procedure; control subjects were administered placebo capsules. The gingiva excised during this surgical procedure were extracted, the extracts partially purified and analyzed for collagenase activity using [3H-methyl] collagen as substrate and the techniques of SDS-PAGE/fluorography or liquid scintillation spectrometry. In the absence of any drug pre-treatment, or after a 2-wk regimen of placebo capsules, the gingival extracts exhibited pathologically-excessive mammalian collagenase activity. The 2-wk regimen of low-dose doxycycline capsules reduced this activity by approximately 60-80% (p less than 0.05 and less than 0.01, respectively); in vitro exposure of the gingival extract to doxycycline also inhibited its collagenase activity. Collagenase activity in the crevicular fluid of periodontal pockets of an additional group of subjects was also significantly reduced, as was the severity of inflammation at the same gingival sites. The results suggest that a regimen of low-dose doxycycline capsules may provide a safe (other studies indicate that this regimen may not induce tetracycline resistance in the subgingival plaque) and effective adjunct to instrumentation therapy in the management of pathologic collagenolysis in the periodontal patient. However, further studies are necessary to confirm this hypothesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177499     DOI: 10.1111/j.1600-0765.1990.tb00923.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  29 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential.

Authors:  K Suomalainen; T Sorsa; L M Golub; N Ramamurthy; H M Lee; V J Uitto; H Saari; Y T Konttinen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  Novel host response therapeutic approaches to treat periodontal diseases.

Authors:  Keith L Kirkwood; Joni A Cirelli; Jill E Rogers; William V Giannobile
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

4.  Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells.

Authors:  Anna Bender; Tamar Zapolanski; Shannon Watkins; Ava Khosraviani; Kristina Seiffert; Wanhong Ding; John A Wagner; Richard D Granstein
Journal:  Exp Dermatol       Date:  2008-03-13       Impact factor: 3.960

5.  Protective action of doxycycline against diabetic cardiomyopathy in rats.

Authors:  N Yaras; M Sariahmetoglu; A Bilginoglu; A Aydemir-Koksoy; A Onay-Besikci; B Turan; R Schulz
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

6.  Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial.

Authors:  R Gapski; J L Barr; D P Sarment; M G Layher; S S Socransky; W V Giannobile
Journal:  J Periodontol       Date:  2004-03       Impact factor: 6.993

Review 7.  Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis.

Authors:  Corneliu Sima; Ana Viniegra; Michael Glogauer
Journal:  J Leukoc Biol       Date:  2018-11-19       Impact factor: 4.962

8.  Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis.

Authors:  A Lauhio; Y T Konttinen; H Tschesche; D Nordström; T Salo; J Lähdevirta; L M Golub; T Sorsa
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Immunization with Porphyromonas (Bacteroides) gingivalis fimbriae protects against periodontal destruction.

Authors:  R T Evans; B Klausen; H T Sojar; G S Bedi; C Sfintescu; N S Ramamurthy; L M Golub; R J Genco
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

Review 10.  Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.

Authors:  J Thomas Peterson
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.